Inhibition of a tumour protease with 3,4-dichloroisocoumarin, pentamidine-isethionate and guanidino derivatives.
M Anees, F S Steven
Index: J. Enzym. Inhib. 8(3) , 213-21, (1994)
Full Text: HTML
Abstract
Guanidinobenzoatase (GB) is a cell surface proteolytic enzyme capable of degrading fibronectin, and is associated with tumour cells and cells capable of migration. The location of active GB in sections has been demonstrated with 9-aminoacridine (9-AA), a competitive inhibitor of GB. 3,4-Dichloroisocoumarin (3,4-DCI) and pentamidine isethionate (PI) are inhibitors of trypsin-like enzymes. It has now been demonstrated that 3,4-DCI, PI, and guanidino derivative compounds are significant inhibitors of GB, on the surfaces of lung squamous cell carcinoma cells in frozen sections and free GB in solution. Dexamethasone acetate (DMA) and medroxy-progesterone (MP) did not show any significant inhibition of GB activity. These molecules lack a reactive chloride or guanidino groups and are thought to react at the nuclear level, rather than directly on this cell surface protease. Kinetic studies have shown that 3,4-DCI, PI and guanidino derivatives are reversible competitive inhibitors of GB, as determined in vitro on the purified enzyme. The inhibition resulting with 3,4-DCI was a time-dependent process. It is suggested that these inhibitors interact with GB by binding to its active site, resulting in the formation of enzyme-inhibiter complexes (GB-I). The GB-I complexes can be dissociated with SDS treatment, resulting in the regain of GB activity.
Related Compounds
Related Articles:
2014-06-06
[J. Chromatogr. A. 1345 , 17-28, (2014)]
Simultaneous determination of 38 veterinary antibiotic residues in raw milk by UPLC-MS/MS.
2015-08-15
[Food Chem. 181 , 119-26, (2015)]
Passive sampling: A cost-effective method for understanding antibiotic fate, behaviour and impact.
2015-12-01
[Environ. Int. 85 , 284-91, (2015)]
DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.
2011-01-01
[Nucleic Acids Res. 39 , D1035-41., (2011)]
Sensitization to oral enoxolone.
1994-02-01
[Contact Dermatitis 30(2) , 124, (1994)]